Profile data is unavailable for this security.
About the company
Tenax Therapeutics, Inc. is a Phase 3 development-stage pharmaceutical company. The Company is focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The Company's products include TNX-201 (oral enteric-coated imatinib) and TNX-103 (oral levosimendan). The Company is developing dosing and a formulation of imatinib mesylate, a kinase inhibitor for the treatment of pulmonary arterial hypertension (PAH). The Company’s other programs include TNX-101 and TNX-102. Levosimendan is a calcium sensitizer/K-ATP activator developed for intravenous use in hospitalized patients with acutely decompensated heart failure. The Company has completed the Phase II trial of levosimendan in patients with PH and heart failure with preserved ejection fraction (HFpEF).
- Revenue in USD (TTM)0.00
- Net income in USD-43.33m
- Incorporated2008
- Employees4.00
- LocationTenax Therapeutics Inc101 GLEN LENNOX DRIVE, SUITE 300CHAPEL HILL 27517United StatesUSA
- Phone+1 (919) 855-2100
- Fax+1 (302) 655-5049
- Websitehttp://www.tenaxthera.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| XBiotech Inc | 0.00 | -29.16m | 72.26m | 88.00 | -- | 0.4325 | -- | -- | -0.9566 | -0.9566 | 0.00 | 5.48 | 0.00 | -- | -- | 0.00 | -15.25 | -7.74 | -16.08 | -8.02 | -- | -- | -- | -187.68 | -- | -- | 0.00 | -- | -- | -- | -56.90 | -- | 44.92 | -- |
| Nuo Therapeutics Inc | 2.61m | -2.43m | 72.42m | -- | -- | -- | -- | 27.73 | -0.0517 | -0.0517 | 0.0555 | -0.0088 | 1.43 | 4.19 | 5.32 | -- | -133.29 | -121.45 | -289.99 | -243.05 | 70.38 | 78.52 | -93.06 | -424.19 | 1.00 | -17,110.33 | -- | -- | 124.34 | 56.34 | 26.73 | -- | -- | -- |
| Ibio Inc | 500.00k | -20.11m | 72.89m | 20.00 | -- | 0.7626 | -- | 145.77 | -1.44 | -1.44 | 0.0232 | 2.77 | 0.0113 | -- | 15.38 | 25,000.00 | -45.35 | -30.90 | -50.81 | -37.76 | -- | -- | -4,021.60 | -2,374.12 | -- | -- | 0.0127 | -- | 77.78 | -24.57 | -19.00 | -- | -57.50 | -- |
| Maia Biotechnology Inc | 0.00 | -22.34m | 72.95m | 13.00 | -- | 1,628.72 | -- | -- | -0.7504 | -0.7504 | 0.00 | 0.0012 | 0.00 | -- | -- | 0.00 | -212.50 | -208.29 | -602.02 | -373.18 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -17.61 | -- | -- | -- |
| Seres Therapeutics Inc | 351.00k | 5.39m | 74.36m | 103.00 | 13.95 | 1.65 | 7.70 | 211.86 | 0.5892 | 0.5892 | 0.0404 | 4.99 | 0.0022 | -- | -- | 3,407.77 | 3.35 | -42.44 | 4.59 | -55.22 | -- | -- | 1,536.75 | -367.23 | -- | -- | 0.00 | -- | -- | -- | 33.85 | -- | -17.63 | -- |
| ImageneBio Inc | 0.00 | -46.14m | 76.59m | 15.00 | -- | 0.5478 | -- | -- | -8.11 | -8.11 | 0.00 | 12.51 | 0.00 | -- | -- | 0.00 | -29.23 | -29.58 | -31.29 | -33.67 | -- | -- | -- | -407.25 | -- | -- | 0.00 | -- | -100.00 | -- | 27.77 | -- | -- | -- |
| Medicinova Inc | 257.92k | -12.01m | 76.67m | 13.00 | -- | 1.74 | -- | 297.26 | -0.2449 | -0.2449 | 0.0053 | 0.8964 | 0.0049 | -- | -- | 19,840.00 | -22.73 | -15.56 | -24.08 | -16.17 | -- | -- | -4,656.61 | -1,144.98 | -- | -- | 0.00 | -- | -100.00 | -- | -28.91 | -- | -39.68 | -- |
| Tenax Therapeutics Inc | 0.00 | -43.33m | 80.67m | 4.00 | -- | 0.7933 | -- | -- | -1.13 | -1.13 | 0.00 | 16.29 | 0.00 | -- | -- | 0.00 | -42.77 | -99.65 | -44.80 | -118.65 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -128.28 | -- | -- | -- |
| Champions Oncology Inc | 58.42m | 2.49m | 82.62m | 213.00 | 35.70 | 19.81 | 20.78 | 1.41 | 0.1667 | 0.1667 | 4.14 | 0.3003 | 2.11 | -- | 5.31 | 274,291.10 | 8.78 | -4.67 | 33.91 | -11.66 | 50.11 | 47.28 | 4.16 | -2.79 | -- | -- | 0.0327 | -- | 13.54 | 12.13 | 164.61 | -- | -29.41 | -- |
| eXoZymes Inc | 0.00 | -8.34m | 84.00m | 31.00 | -- | 15.61 | -- | -- | -1.76 | -1.76 | 0.00 | 0.6408 | 0.00 | -- | -- | 0.00 | -147.87 | -- | -393.50 | -- | -- | -- | -- | -- | -- | -- | 0.0217 | -- | -- | -- | -187.55 | -- | -- | -- |
| Pyxis Oncology Inc | 2.82m | -97.09m | 84.06m | 44.00 | -- | 1.22 | -- | 29.81 | -1.58 | -1.58 | 0.0457 | 1.11 | 0.0187 | -- | -- | 64,090.91 | -64.53 | -47.22 | -74.33 | -53.45 | 0.00 | -- | -3,442.77 | -2,233.63 | -- | -- | 0.0006 | -- | -- | -- | -4.80 | -- | -- | -- |
| TuHURA Biosciences Inc | 0.00 | -43.77m | 84.40m | 19.00 | -- | 4.32 | -- | -- | -1.60 | -1.60 | 0.00 | 0.3273 | 0.00 | -- | -- | 0.00 | -286.97 | -- | -456.76 | -- | -- | -- | -- | -- | -- | -9.01 | 0.0286 | -- | -- | -- | -- | -- | -- | -- |
| aTyr Pharma Inc | 190.00k | -75.12m | 87.30m | 56.00 | -- | 1.09 | -- | 459.45 | -0.8345 | -0.8345 | 0.0021 | 0.8188 | 0.0019 | -- | 0.1323 | 3,392.86 | -75.78 | -47.98 | -88.99 | -54.91 | -- | -- | -39,540.53 | -978.90 | -- | -- | 0.0127 | -- | -33.43 | -11.05 | -27.06 | -- | -3.83 | -- |
| Biomea Fusion Inc | 0.00 | -95.71m | 88.38m | 42.00 | -- | 4.76 | -- | -- | -2.39 | -2.39 | 0.00 | 0.2625 | 0.00 | -- | -- | 0.00 | -115.59 | -62.24 | -156.30 | -68.84 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -18.06 | -- | -- | -- |
| Spruce Biosciences Inc | 697.00k | -47.88m | 88.80m | 9.00 | -- | 8.68 | -- | 127.40 | -84.64 | -84.64 | 1.22 | 9.56 | 0.0173 | -- | -- | 33,190.48 | -119.08 | -43.45 | -161.94 | -49.92 | -- | -- | -6,869.30 | -1,459.77 | -- | -353.48 | 0.091 | -- | -51.32 | -- | -10.68 | -- | -- | -- |
| Dogwood Therapeutics Inc | 0.00 | -39.98m | 89.78m | 12.00 | -- | -- | -- | -- | -24.92 | -24.92 | 0.00 | 33.75 | 0.00 | -- | -- | 0.00 | -81.05 | -52.48 | -84.58 | -55.93 | -- | -- | -- | -- | -- | -178.51 | 0.00 | -- | -- | -- | -142.90 | -- | -- | -- |
Data as of Feb 13 2026. Currency figures normalised to Tenax Therapeutics Inc's reporting currency: US Dollar USD
69.26%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Ikarian Capital LLCas of 30 Nov 2025 | 967.60k | 15.50% |
| Janus Henderson Investors US LLCas of 28 Nov 2025 | 623.73k | 9.99% |
| Perceptive Advisors LLCas of 18 Dec 2025 | 439.14k | 7.03% |
| RTW Investments LPas of 30 Sep 2025 | 378.35k | 6.06% |
| Boothbay Fund Management LLCas of 30 Sep 2025 | 352.21k | 5.64% |
| Dellora Investments LPas of 05 Mar 2025 | 351.07k | 5.62% |
| Point72 Asset Management LPas of 22 Oct 2025 | 339.63k | 5.44% |
| BVF Partners LPas of 30 Sep 2025 | 339.55k | 5.44% |
| Millennium Management LLCas of 30 Sep 2025 | 313.71k | 5.03% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 218.94k | 3.51% |
More ▼
Data from 05 Mar 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
